Overview
Modus Therapeutics Holding AB, based in Sweden, is a biotechnology company focused predominantly on the development of innovative treatments for diseases with significant unmet medical needs. The company’s primary project centers on sevuparin, a proprietary polysaccharide drug designed to restore blood flow and prevent further microvascular obstructions by blocking selectin-mediated interactions in diseases such as sickle cell disease (SCD). This treatment aims to manage acute vaso-occlusive crises (VOCs) associated with SCD, a genetic blood disorder that causes red blood cells to assume an abnormal, rigid, sickle shape. Modus Therapeutics seeks to reduce hospitalizations and improve the quality of life for patients with this debilitating disease through its novel therapeutic approach.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -15.35 MM.
- The net income for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -15.26 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-03-31 | -15.35 | -15.26 | |
| 2024-12-31 | -15.84 | -15.54 | |
| 2024-09-30 | -14.76 | -14.90 | |
| 2024-06-30 | -14.23 | -15.01 | |
| 2024-03-31 | -13.79 | -14.96 | |
| 2023-12-31 | -16.40 | -17.90 | |
| 2023-09-30 | -21.75 | -23.18 | |
| 2023-06-30 | -22.12 | -23.00 | |
| 2023-03-31 | -20.75 | -21.30 | |
| 2022-12-31 | -18.01 | -18.32 | |
| 2022-09-30 | -21.17 | -21.25 | |
| 2022-06-30 | -22.79 | -22.79 | |
| 2022-03-31 | -22.33 | -22.33 | |
| 2021-12-31 | -20.69 | -20.69 | |
| 2021-09-30 | -9.42 | -9.42 | |
| 2021-06-30 | -5.68 | -5.68 | |
| 2021-03-31 | -4.84 | -4.84 | |
| 2020-12-31 | -6.02 | -6.02 |
Income Statement: EPS
- The earnings per share basic for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -0.42.
- The earnings per share diluted for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -0.42.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-03-31 | -0.42 | -0.42 |
| 2024-12-31 | -0.43 | |
| 2024-09-30 | -0.45 | -0.45 |
| 2024-06-30 | -0.54 | -0.54 |
| 2024-03-31 | -0.66 | -0.66 |
| 2023-12-31 | -1.01 | |
| 2023-09-30 | -1.44 | -1.44 |
| 2023-06-30 | -1.42 | -1.42 |
| 2023-03-31 | -1.32 | -1.32 |
| 2022-12-31 | -1.14 | |
| 2022-09-30 | -1.32 | -1.32 |
| 2022-06-30 | -1.44 | -1.44 |
| 2022-03-31 | -1.57 | -1.57 |
| 2021-12-31 | -1.67 | |
| 2021-09-30 | -0.90 | -0.90 |
| 2021-06-30 | -0.52 | -0.52 |
| 2021-03-31 | -0.56 | -0.56 |
| 2020-12-31 | -1.02 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -15.07 MM.
- The cash from financing activities for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is 5.00 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-03-31 | -15.07 | 5.00 | |
| 2024-12-31 | -14.68 | ||
| 2024-09-30 | -14.19 | 18.32 | |
| 2024-06-30 | -13.17 | 20.32 | |
| 2024-03-31 | -14.01 | 22.82 | |
| 2023-12-31 | -16.68 | 25.32 | |
| 2023-09-30 | -21.75 | 7.00 | |
| 2023-06-30 | -21.55 | 16.50 | |
| 2023-03-31 | -20.51 | 14.00 | |
| 2022-12-31 | -21.72 | 11.50 | |
| 2022-09-30 | -21.92 | 0.00 | 11.50 |
| 2022-06-30 | -23.39 | 0.00 | 29.43 |
| 2022-03-31 | -22.46 | -0.05 | 29.43 |
| 2021-12-31 | -16.08 | -0.05 | 29.43 |
| 2021-09-30 | -8.80 | -0.05 | 34.43 |
| 2021-06-30 | -5.51 | -0.05 | 5.00 |
| 2021-03-31 | -5.48 | 10.20 | |
| 2020-12-31 | -7.23 | 13.20 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 |
Management Effectiveness
- The roa for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -0.95.
- The roe for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -1.05.
- The roic for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -3.53.
- The croic for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -2.33.
- The ocroic for Modus Therapeutics Holding AB (publ) - Equity Right as of 31 March 2025 is -3.49.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-03-31 | -0.95 | -1.05 | -3.53 | -2.33 | -3.49 |
| 2024-12-31 | -2.82 | -2.17 | 0.60 | -2.07 | |
| 2024-09-30 | -2.82 | -2.17 | 0.60 | -2.07 | |
| 2024-06-30 | -2.03 | -1.03 | 0.60 | -0.96 | |
| 2024-03-31 | -1.59 | -0.49 | 0.24 | -0.46 | |
| 2023-12-31 | -1.20 | -3.42 | -11.11 | -7.07 | -10.42 |
| 2023-09-30 | -2.13 | -2.38 | -7.23 | -1.59 | -6.78 |
| 2023-06-30 | -2.13 | -2.38 | -7.23 | -1.59 | -6.78 |
| 2023-03-31 | -1.58 | -1.68 | -3.96 | -1.21 | -3.82 |
| 2022-12-31 | -0.72 | -0.76 | -1.16 | -0.57 | -1.20 |
| 2022-09-30 | -0.72 | -0.76 | -1.16 | -0.57 | -1.20 |
| 2022-06-30 | -5.28 | -7.51 | -2.35 | 0.62 | -2.42 |
| 2022-03-31 | -3.44 | -4.01 | -1.76 | 0.55 | -1.77 |
| 2021-12-31 | -0.34 | 0.91 | -0.31 | ||
| 2021-09-30 | -0.34 | 0.91 | -0.31 | ||
| 2021-06-30 | -2.77 | -1.87 | -0.19 | -1.82 | |
| 2021-03-31 | -2.36 | -0.87 | 0.85 | -0.98 | |
| 2020-12-31 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 |
Identifiers and Descriptors
| Central Index Key (CIK) |
